Analysts: Will Infuse storm force Medtronic to jettison spine business? July 5, 2011 By MassDevice staff Leave a Comment MASSDEVICE ON CALL — Sticks and stones may break Medtronic Inc.’s (NYSE:MDT) bone business, as analysts predict that the growing controversy over the company’s Infuse bone-growth product may lead the medical device giant to shed that arm entirely.